481 related articles for article (PubMed ID: 11830312)
41. [Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients].
Liu LP; Yu JM; Guo HB; Fu Z; Han AQ; Yang GR
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):453-6. PubMed ID: 17974282
[TBL] [Abstract][Full Text] [Related]
42. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study.
Ciernik IF; Dizendorf E; Baumert BG; Reiner B; Burger C; Davis JB; Lütolf UM; Steinert HC; Von Schulthess GK
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):853-63. PubMed ID: 14529793
[TBL] [Abstract][Full Text] [Related]
43. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition.
Schreurs LM; Busz DM; Paardekooper GM; Beukema JC; Jager PL; Van der Jagt EJ; van Dam GM; Groen H; Plukker JT; Langendijk JA
Dis Esophagus; 2010 Aug; 23(6):493-501. PubMed ID: 20113320
[TBL] [Abstract][Full Text] [Related]
44. A new method to assess pulmonary changes using
Abravan A; Knudtsen IS; Eide HA; Løndalen AM; Helland Å; van Luijk P; Malinen E
Acta Oncol; 2017 Nov; 56(11):1597-1603. PubMed ID: 28849707
[TBL] [Abstract][Full Text] [Related]
45. [Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma].
Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petenief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Hourry S; Talbot JN
Cancer Radiother; 2005 May; 9(3):152-60. PubMed ID: 16023043
[TBL] [Abstract][Full Text] [Related]
46. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.
Nestle U; Schaefer-Schuler A; Kremp S; Groeschel A; Hellwig D; Rübe C; Kirsch CM
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):453-62. PubMed ID: 17058078
[TBL] [Abstract][Full Text] [Related]
47. Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer.
Macmanus M; D'Costa I; Everitt S; Andrews J; Ackerly T; Binns D; Lau E; Ball D; Weih L; Hicks RJ
Australas Radiol; 2007 Aug; 51(4):386-93. PubMed ID: 17635480
[TBL] [Abstract][Full Text] [Related]
48. [The impact of 18F-fluorodeoxyglucose positron emission tomography on the 3D conformal radiotherapy planning in patients with non-small cell lung cancer].
Bachaud JM; Marre D; Dygai I; Caselles O; Hamelin D; Bègue M; Laprie A; Zerdoud S; Gancel M; Courbon F
Cancer Radiother; 2005 Dec; 9(8):602-9. PubMed ID: 16316759
[TBL] [Abstract][Full Text] [Related]
49. Defining the target in cancer of the oesophagus: direct radiotherapy planning with fluorodeoxyglucose positron emission tomography-computed tomography.
le Grange F; Wickers S; Warry A; Warrilow J; Bomanji J; Tobias JS
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):160-7. PubMed ID: 25540907
[TBL] [Abstract][Full Text] [Related]
50. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515.
Bradley J; Bae K; Choi N; Forster K; Siegel BA; Brunetti J; Purdy J; Faria S; Vu T; Thorstad W; Choy H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):435-41.e1. PubMed ID: 21075551
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
Lin P; Koh ES; Lin M; Vinod SK; Ho-Shon I; Yap J; Som S
Radiother Oncol; 2011 Nov; 101(2):284-90. PubMed ID: 21777988
[TBL] [Abstract][Full Text] [Related]
52. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
[TBL] [Abstract][Full Text] [Related]
53. Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning.
Hanna GG; Van Sörnsen De Koste JR; Carson KJ; O'Sullivan JM; Hounsell AR; Senan S
Br J Radiol; 2011 Oct; 84(1006):919-29. PubMed ID: 21224293
[TBL] [Abstract][Full Text] [Related]
54. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
55. Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features.
van Loon J; Siedschlag C; Stroom J; Blauwgeers H; van Suylen RJ; Knegjens J; Rossi M; van Baardwijk A; Boersma L; Klomp H; Vogel W; Burgers S; Gilhuijs K
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):448-56. PubMed ID: 20971575
[TBL] [Abstract][Full Text] [Related]
56. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
57. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.
Leong T; Everitt C; Yuen K; Condron S; Hui A; Ngan SY; Pitman A; Lau EW; MacManus M; Binns D; Ackerly T; Hicks RJ
Radiother Oncol; 2006 Mar; 78(3):254-61. PubMed ID: 16545881
[TBL] [Abstract][Full Text] [Related]
58. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?
Peeters ST; Dooms C; Van Baardwijk A; Dingemans AM; Martinussen H; Vansteenkiste J; Decaluwé H; De Leyn P; Yserbyt J; Nackaerts K; De Wever W; Deroose CM; De Ruysscher D
Radiother Oncol; 2016 Aug; 120(2):273-8. PubMed ID: 27291644
[TBL] [Abstract][Full Text] [Related]
59. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Houry S; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):340-5. PubMed ID: 16168829
[TBL] [Abstract][Full Text] [Related]
60. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
